Product news

Share this article:
Gilead Sciences has received FDA approval for the marketing of Viread (tenofovir disoproxil fumarate), for the treatment of chronic hepatitis B in adults. Viread has been available in the US for the treatment of HIV infection in adults since 2001.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.